We are at a crossroads in the evolution of care for patients with multiple myeloma and related disorders.
The past decade has seen the introduction of a wealth of new therapies that have resulted in great improvement in the outcomes of patients with much longer remissions. However, relapse remains inevitable and myeloma remains essentially incurable. We now have the opportunity to integrate these new technologies with evolving insights into the biology of myeloma to achieve something that has to date eluded us, curing significant numbers of patients.
John Theurer Cancer Center has already built one of the best and most active clinical multiple myeloma programs in the world, exploring every legitimate therapeutic option available and becoming one of the most consistent conduits of drug development in myeloma. We seek to transform the treatment of patients with multiple myeloma by integrating our enormous clinical expertise and research contributions with ongoing basic and translational research. The Institute for Multiple Myeloma and Lymphoma will represent a true “clinical laboratory” for multiple myeloma including real world, research-grade data over time, and access to clinical material over the continuum of care.
Our patients have contributed so much to an understanding of this horrible disease. It is now time to leverage our shared vision, talents, and accumulated knowledge and expertise into a comprehensive Institute – an integrated clinical, laboratory, and population science-based research center – that will exponentially expand our fight against multiple myeloma and expedite a cure.
David S. Siegel M.D., Ph.D.
Chief and Founder of the Multiple Myeloma Division
John Theurer Cancer Center, Hackensack Meridian Health